02096.HK
Simcere Pharmaceutical Group Limited
HKSE · Healthcare · Biotechnology · CN
HKD 10.14
−2.31%Year over year
Reported trailing growth
- Revenue
- +21.9%
- EBITDA
- +27.3%
- EBIT
- +74.3%
- EPS
- +72.8%
- Free cash flow
- +115.4%
- Operating cash flow
- +133.1%
Forward estimates
Based on analyst estimates
- Revenue
- -47.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +7.0%
- EBITDA
- +26.4%
- EBIT
- +21.7%
- Net income
- +13.0%
- EPS
- +14.5%
- Free cash flow
- +19.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026